MAGLE CHEMOSWED HOLDING AB (PUBL) ADVANCES PUBLICATION OF THE INTERIM REPORT FOR Q2 2026
Magle Chemoswed Holding AB (publ) ("Magle Group") hereby announces that the publication of the interim report for the period 1 January – 30 June 2026 has been advanced to 12 August 2026.
The advancement is due to the work on the interim report having progressed faster than planned. The originally communicated publication date was on 14 August 2026. The interim report will instead be published on 12 August 2026 and made available on Magle Group's website, https://maglegroup.com/.
Contacts
Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. Today, the Group includes two operational areas. Magle Chemoswed – a contract manufacturing organization (CMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle Biopolymers A/S - a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglebiopolymers.com
Redeye Nordic Growth AB is the company's Certified Adviser.